Posted by Michael Wonder on 11 May 2021
Avenda Health granted FDA breakthrough device designation for technology to treat prostate cancer
11 May 2021 - Avenda Health advances male “lumpectomy” for prostate cancer with new in office, AI based focal therapy system.
Breakthrough Device Designation was awarded to Avenda Health for a male “lumpectomy” product in development designed to treat prostate cancer in-office while preserving quality of life.
Avenda Health is a California based software and medical device company aiming to improve cancer outcomes through artificial intelligence and minimally invasive technologies.
